Amanote Research
Register
Sign In
Comparison of Tyrosine Kinase Inhibitor Versus Mammalian Target of Rapamycin Inhibitor as Second-Line Molecular-Targeted Therapy for Patients With Poor-Risk Metastatic Renal Cell Carcinoma
Anticancer Research
- Greece
doi 10.21873/anticanres.11480
Full Text
Open PDF
Abstract
Available in
full text
Categories
Medicine
Cancer Research
Oncology
Date
March 17, 2017
Authors
Unknown
Publisher
International Institute of Anticancer Research
Related search
Tyrosine Kinase Inhibitor and Target Therapy
Patient-Specific Molecular Alterations Are Associated With Metastatic Clear Cell Renal Cell Cancer Progressing Under Tyrosine Kinase Inhibitor Therapy
Oncotarget
Oncology
Molecular Subtyping of Metastatic Renal Cell Carcinoma: Implications for Targeted Therapy
Molecular Cancer
Cancer Research
Oncology
Molecular Medicine
Temsirolimus, an Inhibitor of Mammalian Target of Rapamycin
Clinical Cancer Research
Cancer Research
Oncology
Tumor Genetic Analyses of Patients With Metastatic Renal Cell Carcinoma and Extended Benefit From mTOR Inhibitor Therapy
Clinical Cancer Research
Cancer Research
Oncology
Mammalian Target of Rapamycin Inhibitor–Associated Stomatitis in Hematopoietic Stem Cell Transplantation Patients Receiving Sirolimus Prophylaxis for Graft-Versus-Host Disease
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Do Tyrosine Kinase Inhibitors Lose Favor in Treatment of First-Line Metastatic Renal Cell Carcinoma?
Future Oncology
Medicine
Cancer Research
Oncology
Metastatic Adamantinoma Responds to Treatment With Receptor Tyrosine Kinase Inhibitor
Acta Oncologica
Nuclear Medicine
Radiology
Hematology
Oncology
Medicine
Imaging
Correction: An ATP-competitive Mammalian Target of Rapamycin Inhibitor Reveals Rapamycin-Resistant Functions of mTORC1.
Journal of Biological Chemistry
Biochemistry
Cell Biology
Molecular Biology
